Aditxt, Inc. (ADTX) Stock Price & Analysis
Aditxt, Inc. (ADTX) fell 42.08% to USD 0.03 as of June 10, 2026 at 03:07 UTC, according to Nexqual real-time market data.
ADTX last closed at USD 0.05; the session ranged USD 0.03–0.04 on volume of 374,840,306 shares. Market capitalization is $23,580, with a 52-week range of USD 0.03–53,453.52 (NCM). Source: Nexqual, June 10, 2026 at 03:07 UTC.
Key Statistics (as of June 10, 2026 at 03:07 UTC)
| Price | USD 0.03 |
|---|---|
| Change | ▼ 42.08% (down) |
| Previous Close | USD 0.05 |
| Open | USD 0.04 |
| Day Range | USD 0.03 – 0.04 |
| 52-Week Range | USD 0.03 – 53,453.52 |
| Volume | 374,840,306 shares |
| Market Cap | $23,580 |
| Exchange | NCM |
Technical Analysis (ADTX)
Nexqual's technical model rates ADTX "SELL" based on 2 bullish and 5 bearish signals across 124 daily candles, as of June 10, 2026 at 03:07 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 1.07 (oversold) |
| vs SMA50 | Below (USD 6.63) |
| MACD | -2.8 (negative) |
Analyst Ratings (ADTX)
Wall Street analysts rate ADTX "None", per Nexqual as of June 10, 2026 at 03:07 UTC.
| Consensus Rating | None |
|---|
Earnings (ADTX)
Source: Nexqual, June 10, 2026 at 03:07 UTC.
Financials & Fundamentals (ADTX)
| Total Revenue | $14,336 |
|---|---|
| Revenue Growth (YoY) | +1094.40% |
| Gross Margin | +19.89% |
| Operating Margin | -35873.53% |
| Profit Margin | +0.00% |
| Current Ratio | 0.06 |
| Total Cash | $268,852 |
| Total Debt | $4.23M |
| Free Cash Flow | $-12.35M |
Source: Nexqual, June 10, 2026 at 03:07 UTC.
Financial Health Score (ADTX)
Nexqual rates Aditxt, Inc.'s overall financial health "Weak" across five dimensions, as of June 10, 2026 at 03:07 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Critical — Heavily loss-making — early-stage company |
| Balance Sheet | Mixed — $269K cash vs $4M debt |
| Cash Flow | Weak — FCF negative: -$12M, burning cash |
| Efficiency | Mixed — No data |
Ownership (ADTX)
| Insider Ownership | +0.09% |
|---|---|
| Institutional Ownership | +0.22% |
| Shares Outstanding | 815,921 |
| Float | 815,921 |
| Short % of Float | +11.44% |
Source: Nexqual, June 10, 2026 at 03:07 UTC.
Leadership (ADTX)
Aditxt, Inc. is led by Thomas J. Farley (age 51), Chief Financial Officer, per Nexqual as of June 10, 2026 at 03:07 UTC.
| Chief Financial Officer | Thomas J. Farley (age 51) |
|---|
From Aditxt, Inc.'s Latest SEC 10-K Filing (filed 2026-03-31)
Key Strengths & Strategy (as disclosed to the SEC)
- Aditxt, Inc. focuses on discovery and development of biopharmaceutical products.
- The company develops AditxtScore and FlowSpot that enable individuals to understand, manage, and monitor their immune profiles in order to be informed about attacks on or by their immune system; and Apoptotic DNA Immunotherapy, a nucleic acid-based technology that utilizes an approach that mimics the way the body naturally induces tolerance to its tissues.
- It develops ADI-100 for skin grafting, psoriasis, and type-1 diabetes.
- In addition, the company provides Pearsanta that develops molecular tests based on the mitochondrial DNA (mtDNA) to develop tests for early detection of cancer; Mitomic targets mutations in mitochondrial DNA (mtDNA) to detect disease; Mitomic prostate test a blood-based assay that quantifies the level of the 3.4kb mtDNA deletion; and Mitomic endometriosis test, a blood-based assay that quantifies the level of one or more mtDNA deletions.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| ENSC | Ensysce Biosciences, Inc. | USD 0.25 | ▲ 0% |
| ADIL | Adial Pharmaceuticals, Inc | USD 2.13 | ▼ 3.62% |
| RKTO | Rocket One Inc. | USD 1.28 | ▼ 15.23% |
| DBGI | Digital Brands Group, Inc. | USD 1.07 | ▲ 24.42% |
| PALI | Palisade Bio, Inc. | USD 1.69 | ▼ 2.87% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 03:07 UTC. This page is informational and not investment advice.